Birznieks Gunther
SEC CIK 1702031 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals Inc. | SVP, Business Development | 494.2K | — | $704.3K | 11 | 2022-02-28 | 2026-03-02 |
Most active insiders at VNDA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Polymeropoulos Mihael Hristos | Pres, CEO, Dir, COB | — | $1.28M |
| 2 | Moran Kevin Patrick | SVP, CFO, Treas | — | $351.0K |
| 3 | Williams Timothy | SVP, GC | — | $350.9K |
| 4 | Birznieks Gunther | SVP, Business Development | — | $350.9K |
| 5 | Wijkstrom Joakim | SVP, CMO | — | $254.7K |
| 6 | Honore Tage | Dir | — | $240.9K |
| 7 | McGuire Daniel Patrick | SVP, GC, Sec | — | — |
| 8 | Duncan Charles Cliff | Dir | — | — |
| 9 | Mitchell Stephen Ray | Dir | — | — |
| 10 | Ward Anne Sempowski | Dir | — | — |
Transactions 11
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | 2026-03-02 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | S - Sale | $8.27 | -42.4K | 494.2K | -8% | -$350.9K | |
| 2026-02-19 | 2026-02-18 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | A - Grant | $0.00 | +125.0K | 536.6K | +30% | $0 | |
| 2025-03-04 | 2025-03-01 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | F - Tax | $4.76 | -26.9K | 411.6K | -6% | -$128.2K | |
| 2025-02-20 | 2025-02-18 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | A - Grant | $0.00 | +125.0K | 438.6K | +40% | $0 | |
| M | 2024-03-06 | 2024-03-04+ | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | S - Sale | $4.22 | -17.4K | 313.6K | -5% | -$73.4K |
| 2024-02-21 | 2024-02-16 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | A - Grant | $0.00 | +125.0K | 331.0K | +61% | $0 | |
| M | 2023-03-06 | 2023-03-02+ | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | S - Sale | $6.23 | -16.8K | 206.0K | -8% | -$104.5K |
| D | 2023-02-21 | 2023-02-16 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | A - Grant | $0.00 | +32.7K | 222.8K | +17% | $0 |
| D | 2022-08-29 | 2022-08-26 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | M - OptEx | $3.12 | +1,250 | 190.1K | +0.7% | +$3,900 |
| DM | 2022-03-02 | 2022-03-01+ | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | S - Sale | $11.25 | -15.6K | 188.8K | -8% | -$175.5K |
| D | 2022-03-02 | 2022-02-28 | VNDA | Vanda Pharmaceuticals Inc. | Birznieks Gunther | SVP, Business Development | A - Grant | $0.00 | +32.7K | 204.4K | +19% | $0 |
Purchase Sale Sale after option exercise All abbreviations